Spero Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
675 Massachusetts Ave Ste 14, Cambridge,...Phone Number
(857) 242-1600Website
www.sperotherapeutics.comRevenue
$66.8 MillionStock Symbol
SPROIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
4
1
1
1
1
About Spero Therapeutics
Spero Therapeutics provides therapies for treating highly resistant bacterial infections. Its headquarters is located in Cambridge, Massachusetts.Explore more
Spero Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Spero Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Spero Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Spero Therapeutics has new funding data
Earning: See what the market has to say on Spero Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Spero Therapeutics
Check if Spero Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Spero Therapeutics launches new products
Check out if Spero Therapeutics is spiking on competitors!
Click to see if Spero Therapeutics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Spero Therapeutics
Compare insights from companies similar to Spero Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Spero Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Spero Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Spero Therapeutics.
Spero Therapeutics financials insights
Gather financial insights about Spero Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$33M
2016
Series B
$30M
2017
Series C
$51.7M
Grant
$6.8M
2018
Grant
$54.2M
2019
Grant
$5.9M
2021
Debt
$125M
Spero Therapeutics Tech Stack
A closer look at the technologies used by Spero Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Pharmaceuticals
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Partnership
Spero Therapeutics has entered into an agreement with GSK, granting them an exclusive license to develop and commercialize Pevipenem HBR in all territories except Japan and certain other Asian countries covered by Spero Therapeutics's partnership with Meiji Seika Pharmaco. The agreement includes potential milestone payments of up to $350 million and tiered royalties on net sales.
Partnership, Pharmaceuticals
Earnings
Earnings, Business Finance, Finance
Spero Therapeutics News & Media
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the first quarter ended March 31, 2026, and provide a business update on Wednesday, May 13, 2026, after market close. The Company does not intend to host a conference call.Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call.SEC Institutesd Cease-and-Desist to Former Spero CEO and CFO - The National Law Review
Securities and Exchange Commission instituted settled cease‑and‑desist proceedings against Ankit Mahadevia and Satyavrat Shukla, of Spero Therapeutics Inc. for misle
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Spero Therapeutics
Sign Up For FreeTo access detailed company insights
Spero Therapeutics provides therapies for treating highly resistant bacterial infections. Its headquarters is located in Cambridge, Massachusetts.... Read More
